HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
3- ((2- nitroimidazol- 1- yl)methoxy)butane- 1,2- 4- triol
structure in first source
Also Known As:
PR-000350
Networked:
1
relevant articles (
0
outcomes,
0
trials/studies)
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Azoles: 2138
Imidazoles: 150
3-((2-nitroimidazol-1-yl)methoxy)butane-1,2-4-triol: 1
Experts
1.
Kuno, Y
: 1 article (02/2000)
2.
Shinomiya, N
: 1 article (02/2000)
Related Diseases
1.
Neoplasms (Cancer)
02/01/2000 - "
These results suggest that PR-000350 strongly enhances tumor cell killing by promoting X-ray induced-apoptosis preferentially in the S-phase fraction.
"
02/01/2000 - "
PR-000350, a novel hypoxic radiosensitizer, enhances tumor cell killing by promoting apoptosis preferentially in the S-phase fraction.
"
02/01/2000 - "
PR-000350 is a new type radiosensitizer and promise to provide an effective anti-cancer activity against hypoxic tumor cells that are resistant to the usual radiotherapy.
"
02/01/2000 - "
PR-000350, a novel hypoxic radiosensitizer, is a 2-nitroimidazole nucleoside analog and has begun to be used for clinical cancer therapy.
"
Related Drugs and Biologics
1.
Nucleosides
2.
azomycin
Related Therapies and Procedures
1.
Therapeutics
2.
Radiotherapy